It has been demonstrated that there is an association of germline CHEK2 variants with breast and prostate cancer but some of the data (VUS classification, patients’ geographic distribution, comprehensive CHEK2 mutation analysis) is heterogenous [70]. The gene discussed is CHEK2; the disease is prostate carcinoma.